Last reviewed · How we verify
Remi 0.2
Remi 0.2 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine.
Remi 0.2 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | Remi 0.2 |
|---|---|
| Also known as | remifentanil, Ultiva, Glaxo Wellcome, Marly-le-Roi, France |
| Sponsor | Dokuz Eylul University |
| Drug class | SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
This dual-action mechanism allows for increased levels of these neurotransmitters in the brain, which can help improve mood and reduce symptoms of depression. By inhibiting the reuptake of serotonin and norepinephrine, Remi 0.2 can help increase the amount of time these neurotransmitters are available to bind to their receptors, leading to improved mood and reduced symptoms of depression.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Insomnia
Key clinical trials
- Remifentanil-dexmedetomidine Anesthesia With a Caudal for Elective Surgery. (Remi-dex) (PHASE4)
- Remifentanil on Hemodynamic Response to Anesthesia Induction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remi 0.2 CI brief — competitive landscape report
- Remi 0.2 updates RSS · CI watch RSS
- Dokuz Eylul University portfolio CI